Trials / Completed
CompletedNCT01891019
Thalidomide in the Treatment of Chronic Plaque Psoriasis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Wake Forest University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to obtain information on the effectiveness of thalidomide in psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thalidomide oral | Thalidomide will be administered nightly, with each subject taking 2 capsules totaling 100 milligrams for the initial two weeks of treatment, 3 capsules totaling 150 milligrams for week 2 to week 4, and 4 capsules totaling 200 milligrams for week 4 to end of treatment. The subjects will take the medication for 12 weeks. |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2005-09-01
- Completion
- 2009-06-01
- First posted
- 2013-07-02
- Last updated
- 2018-08-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01891019. Inclusion in this directory is not an endorsement.